快讯摘要 快讯正文 【美国生物制药公司Fusion Pharmaceuticals(FUSN.US)今日盘前股价飙涨94%,报20.65美元。据悉,阿斯利康计划斥资约20亿美元现金收购Fusion Pharmaceuticals,以扩大其肿瘤产品组合。交易价格为每股21美元,较周一收盘价溢价逾97%。此外,阿斯利康还将支付每股3美元的不可转让或有价值权,使整个交易价值达到约24...
TD Cowen:下调Fusion Pharmaceuticals(FUSN.US)评级,由买入调整至持有评级。 Fusion Pharmaceuticals(FUSN.US)公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。该公司结合其专有的Fast-Clear连接剂技术开发靶向α疗法(TAT)。该公司的主要候选产品包括FPI-1434,一种治疗...
we focus on analyzing Fusion Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Fusion Pharmaceuticals's daily price indicators and compare them against related drivers, such asmomentum indicatorsand various other typ...
美股盘前三大股指期货走低,道指期货暂跌0.05%;热门中概股盘前涨跌互现;阿斯利康将以20亿美元现金收购Fusion Pharmaceuticals;辉瑞拟以 7.85美元/股增发Haleon股票;华米科技Q4营收同比下降44.0% 。
Nonetheless, AMD has a consensus “Strong Buy” rating. Out of the 38 analysts covering the stock 29 recommend “Strong Buy,” one advises “Moderate Buy,” and eight suggest “Hold” rating. It’s mean price target of $185.86 indicates a 60.2...
Singh covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Eloxx Pharmaceuticals, and Viracta Therapeutics. Currently, the analyst consensus on Biomea Fusion is a Strong Buy with an average price target of $47.20. See the top stocks recommended by...
I’ve been in Manhattan for twenty some years and worked in pharmaceuticals at a big company in the city. In the corporate world I experienced all manner of office politics, backstabbing, etc. but that was corporate life in the big city. I retired a few years back and have enjoyed ...
Several monoclonal antibody (mAb)-based therapies, including those developed by Regeneron Pharmaceuticals (REGEN-COV) and Eli Lilly (bamlanivimab and etesevimab together), have also been authorized by the FDA for emergency use against COVID-19; however, their high costs and limited accessibility ...